BSR News Archive

2014 

National clinical audit for rheumatoid and early inflammatory arthritis included in Quality Accounts - 19 December 2014

Situation at Greater Western Hospitals FT shines a light on a UK-wide challenge - 15 December 2014

BSR Chief Executive comments on ABPI report - 11 December 2014

Past BSR President reports from Congress in Jordan - 24 November 2014

BSR Chief Executive comments on the Coalition for Collaborative Care initiative - 23 November 2014

BSR response to the NHS 5 Year Forward View - 4 November 2014

Anne Mawdsley, MBE, 1942-2014 - 21 Oct 2014

BSR represented at party conferences - 02 Oct 2014

Improved treatment for patients presenting with rheumatoid and early inflammatory arthritis - 18 Jul 2014

BSR supports Health Committee report to provide effective care to those with long-term conditions, including arthritis - 03 Jul 2014

Disabling effects of rheumatoid arthritis mean patients need six times more sickness absence than average - 16 Jun 2014 

Vitamin D deficiency is associated with the development of chronic widespread pain - 29 Apr 2014 

Arthritis patients want more psychological and emotional support - 16 Apr 2014

Biologics do not increase cancer risk for rheumatoid arthritis patients - 26 Mar 2014

Class, ancestry and medication are factors in cardiac risk for lupus patients - 14 Mar 2014

Test results delay RA patient referrals - 07 Mar 2014      

Young arthritis sufferers choose treatments that ‘make life normal’ - 10 Feb 2014

Rheumatology journal appoints new editor - 01 Feb 2014 

Breastfeeding associated with lower risk of rheumatoid arthritis - 07 Jan 2014 


2013






















2012

BSR Press Release: Time to stop laughing at Gout - 21 November 2012


2011

BSR and SSR respond to BMJ letter - 12 October 2011

New BSR chief – 12 September 2011

New biologics register – 6 September 2011

Golimumab for the treatment of ankylosing spondylitis - 24 August 2011

Abatacept for the treatment of rheumatoid arthritis
- 24 June 2011

Golimumab for the treatment of rheumatoid arthritis - 13 May 2011

Golimumab for the treatment of Psoriatic Arthritis - 17 March 2011


2010

BSR statement: NICE FAD on Tocilizumab for the treatment of RA - 2 July 2010

Health inequalities must be tackled by a National Clinical Director - 30 March 2010

BSR response to report from the Public Accounts Committee into Services for People with RA
- March 2010

BSR statement on NICE decision on use of Certolizumab pegol for rheumatoid arthritis - 21 January 2010


2009

BSR statement on NAO report: Services for People with Rheumatoid Arthritis - 15 July 2009

Swine flu and rheumatology patients - 14 July 2009


2008

NICE appraisal for adalimumab, etanercept and infliximab for RA after failure of a previous anti-TNF
- 24 November 2008

ARMA's statement on NICE's decision on switching Anti-TNF for RA - 21 July 2008

BSR response to the Health Select Committee report on MMC - 9 May 2008

BSR statement in support of the Lancet Report on NICE - 8 May 2008

BSR statement on alcohol and arthritis - May 2008

BSR statement on the sequential use of adalimumab, etanercept and infliximab for rheumatoid arthritis - April 2008

BSR statement on NICE Appeal Committee’s decision on Abatacept for rheumatoid arthritis - April 2008

BSR statement on Gout
- February 2008


2007

BSR statement on Lumiracoxib
- 19 November 2007

BSR statement on NICE decision on use of Rituximab for rheumatoid arthritis - 22 August 2007

BSR statement on the NICE document on Abatacept for rheumatoid arthritis
- 2 August 2007

BSR statement on the NICE appeal for the use of alternative anti-TNF - 12 June 2007


2006

BSR statement on launch of Musculoskeletal Services Framework (MSF) - 1 November 2006

BSR Statement on the Musculoskeletal Services Framework - 8 September 2006

EMEA Announcement on NSAIDS - 25 October 2006

Statement on Choose and Book Keywords & Clinic Types - 16 October 2006

NPSA reissues methotrexate guidance - July 2006